Skip to main content
Year archive

Hansa Biopharma — 2022 filings

All 48 regulatory filings released by Hansa Biopharma (HNSA) in 2022, sourced directly from the official regulator.

48 Filings
2022 Period
2022 filings (48)
Filing Released Lang
Hansa Biopharma: Ökning av antalet aktier och röster
Share Issue/Capital Change
2022-12-30 Swedish
Hansa Biopharma: Increase of the number of shares and votes
Share Issue/Capital Change
2022-12-30 English
Rättelse: Hansa Biopharmas valberedning utsedd
Board/Management Information
2022-12-28 Swedish
Correction: Hansa Biopharma Nomination Committee formed
Board/Management Information
2022-12-28 English
Hansa Biopharmas valberedning utsedd
AGM Information
2022-12-23 Swedish
Hansa Biopharma Nomination Committee formed
Board/Management Information
2022-12-23 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-12-16 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-14 English
Hansa Biopharma har framgångsrikt genomfört en riktad nyemission om 416 MSEK (~40 MUSD)
Capital/Financing Update
2022-12-13 Swedish
Hansa Biopharma announces successful execution of a directed share issue of SEK 416 million (~USD 40 million)
Capital/Financing Update
2022-12-13 English
Hansa Biopharma presenterar positiva första data från fas 2-studien med imlifidase för antikroppsmedierad avstötning (AMR) efter njurtransplantation
Regulatory Filings
2022-11-28 Swedish
Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
Regulatory Filings
2022-11-28 English
Hansa Biopharma planerar att under 2023 tillsammans med sin samarbetspartner Sarepta Therapeutics inleda en klinisk studie av imlifidase som förbehandling till Sareptas genterapi SRP-9001 mot DMD
Regulatory Filings
2022-11-02 Swedish
Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta’s SRP-9001 gene therapy in DMD in 2023
Regulatory Filings
2022-11-02 English
Hansa Biopharma: Ökning av antalet röster
Declaration of Voting Results & Voting Rights Announcements
2022-10-31 Swedish
Hansa Biopharma: Increase of the number of shares and votes
Share Issue/Capital Change
2022-10-31 English
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-10-20 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-10-20 English
Hansa Biopharma: Ökning av antalet aktier och röster
Share Issue/Capital Change
2022-09-30 Swedish
Hansa Biopharma: Increase of the number of shares and votes
Share Issue/Capital Change
2022-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-15 English
Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
Transaction in Own Shares
2022-09-09 English
Hansa Biopharma: Emission och återköp av C-aktier för incitamentsprogram
Transaction in Own Shares
2022-09-09 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report H1 2022
2022-07-19 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report H1 2022
2022-07-19 English
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform
Capital/Financing Update
2022-07-18 English
Hansa Biopharma offentliggör en produktfinansieringstransaktion, utan utspädningseffekt, om 70 MUSD med NovaQuest. Transaktionen stödjer den fortsatta utvecklingen av Hansas enzymteknologiplattform
Capital/Financing Update
2022-07-18 Swedish
Ökning av antalet röster i Hansa Biopharma
Declaration of Voting Results & Voting Rights Announcements
2022-06-30 Swedish
Increase of the number of votes in Hansa Biopharma
Declaration of Voting Results & Voting Rights Announcements
2022-06-30 English
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
AGM Information
2022-06-30 English
Kommuniké från årsstämma i Hansa Biopharma AB (publ)
AGM Information
2022-06-30 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-23 English
NICE rekommenderar Hansa Biopharmas läkemedel Idefirix® (imlifidase) för desensitiseringsbehandling av högsensitiserade njurtransplantationspatienter
Regulatory Filings
2022-06-16 Swedish
NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Regulatory Filings
2022-06-16 English
Hansa Biopharma: Notice to Annual General Meeting
AGM Information
2022-05-30 English
Hansa Biopharma: Kallelse till årsstämma
AGM Information
2022-05-30 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-21 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-21 English
Annual Report 2021
Annual Report FY 2021
2022-04-07 English
Annual Report 2021
Annual Report FY 2021
2022-04-07 Swedish
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Legal Proceedings Report
2022-03-15 English
Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Regulatory Filings
2022-02-25 English
Franska Haute Autorité de Santé har fattat ett positivt beslut att ge tidig tillgång till Hansa Biopharmas Idefirix® (imlifidase) för desensitiseringsbehandling av högsensitiserade njurpatienter
Regulatory Filings
2022-02-25 Swedish
Earnings Release 2021
Earnings Release Q4 2021
2022-02-03 Swedish
Audit Report / Information 2021
Audit Report / Information FY 2021
2022-02-03 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-01-10 English
Hansa Biopharma ingår avtal med AskBio för att utvärdera imlifidas som förbehandling till genterapi vid Pompes sjukdom
M&A Activity
2022-01-03 Swedish
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease
Regulatory Filings
2022-01-03 English